NewsRSS3 days ago
A person who was diagnosed with limb-girdle muscular dystrophy 30 years ago finally took a genetic test to find out exactly which gene mutation caused their condition. Genetic testing can help doctors understand the specific type of muscular dystrophy a patient has, which may affect treatment options and family planning decisions. This story shows how genetic testing technology has improved over time and can provide answers even decades after an initial diagnosis.
WHY IT MATTERSGenetic confirmation of limb-girdle muscular dystrophy can unlock access to gene-specific clinical trials and emerging therapies that weren't available at the time of initial diagnosis.
PolicyRSSApr 16
The FDA is inviting companies that make testosterone replacement therapy drugs to apply for approval of a new use: treating low sex drive in men with a specific condition called idiopathic hypogonadism (when the body doesn't make enough testosterone for unknown reasons). This is an early step that could lead to new treatment options for men with this condition.
WHY IT MATTERSMen with idiopathic hypogonadism who experience low libido may soon have an FDA-approved treatment option specifically designed for this symptom, rather than relying on off-label use of existing testosterone therapies.
ResearchBIORXIVApr 2
Researchers discovered that mutations in a gene called THAP12 cause a severe type of childhood epilepsy called developmental and epileptic encephalopathy. Two siblings with this condition had two broken copies of the THAP12 gene (one from each parent), which stopped the gene from making enough of its protein. This finding helps explain why some children develop severe seizures early in life and could lead to better diagnosis and treatment options.
WHY IT MATTERSFamilies with children diagnosed with infantile spasms or Lennox-Gastaut syndrome now have a new genetic cause to test for, which could explain their child's condition and guide future treatment decisions.
AdvocacyRSSMar 26
NORD, a major rare disease organization, is partnering with OpenEvidence to create AI-powered tools that help doctors and patients find reliable information about rare diseases. This partnership aims to make it easier for people worldwide to access trustworthy resources about their conditions and treatment options.
WHY IT MATTERSThis partnership could help patients with rare diseases get faster access to accurate, expert-reviewed information from their doctors, potentially reducing diagnostic delays and improving treatment decisions.
ResearchPUBMEDMar 26
Scientists are developing tiny particles called exosomes that can deliver cancer-fighting medicines directly to rare cancer tumors. These natural particles act like delivery trucks, carrying drugs to cancer cells while reducing damage to healthy cells. Early research shows this approach could help rare cancer patients who currently have few treatment options.
WHY IT MATTERSPatients with rare cancers often lack targeted treatments and face delayed diagnoses—exosome-based therapies could provide new options by delivering drugs more effectively to tumors while causing fewer side effects.